Showing 5541-5550 of 5621 results for "".
- Gene Therapies That Could Transform Diseases Get Easier FDA Pathhttps://modernod.com/news/gene-therapies-that-could-transform-diseases-get-easier-fda-path/2480144/New therapies that may cure diseases caused by defective genes will get a faster path to approval by U.S. regulators, part of an effort by the FDA to keep pace with one of biotechnology’s fastest-growing fields, according to a Bloomberg
- Researchers Identify Genetic Variants that May Predict Glaucoma Riskhttps://modernod.com/news/researchers-identify-genetic-variants-that-may-predict-glaucoma-risk/2480146/A study led by scientists from King’s College London, University College London, Massachusetts Eye and Ear, and Harvard Medical School has identified 133 genetic variants that could help predict the risk of developing glaucoma, the world’s leading cause of incurable blindness.
- Aerie Submits New Drug Application to FDA for Roclatanhttps://modernod.com/news/aerie-submits-new-drug-application-to-fda-for-roclatan/2480148/Aerie Pharmaceuticals announced the submission of its new drug application (NDA) to the FDA for Roclatan (netarsudil/latanoprost ophthalmic solution) .02%/.005%. Roclatan is a once-daily eye drop designed to reduce IOP in patients with glaucoma or ocular hypertension. It is a fixed dose combinati
- Genome Surgery for Eye Disease Moves Closer to Realityhttps://modernod.com/news/genome-surgery-for-eye-disease-moves-closer-to-reality/2480154/Researchers from Columbia University have developed a new technique for the powerful gene editing tool CRISPR to restore retinal function in mice afflicted by a degenerative retinal disease, retinitis pigmentosa. This is the first time researchers have successfully app
- Retinal Changes on OCT Angiography May Flag Early Alzheimer’shttps://modernod.com/news/retinal-changes-on-oct-angiography-may-flag-early-alzheimers/2480158/Microvascular changes in the retina detected by using noninvasive optical coherence tomography (OCT) angiography align well with imaging and biomarker evidence of preclinical Alzheimer’s disease, a new study shows, according to a Medscape
- Kala Pharmaceuticals Strengthens Commercial Organization in Preparation for First Product Launchhttps://modernod.com/news/kala-pharmaceuticals-strengthens-commercial-organization-in-preparation-for-first-product-launch/2480159/Kala Pharmaceuticals announced the following key commercial hires in preparation for the potential approval and launch of Inveltys, a twice-daily steroid eye drop in development for the treatment of inflammation and pain following ocular surgery: Kathleen McCann Kline, Vice President
- Eye Health America Appoints Cathleen McCabe, MD, as Chief Medical Officerhttps://modernod.com/news/eye-health-america-appoints-cathleen-mccabe-md-as-chief-medical-officer/2480162/Eye Health America (EHA) has appointed Cathleen McCabe, MD, as its chief medical officer. As the newest member of EHA’s executive leadership team, Dr. McCabe will be responsible for the development, implementation, and continuation of best practices across EHA’s group practices and ambulatory sur
- Bausch + Lomb Launches Lumify, the First OTC Redness Relieving Eye Drop With Low-Dose Brimonidinehttps://modernod.com/news/bausch-lomb-launches-lumify-the-first-otc-redness-relieving-eye-drop-with-low-dose-brimonidine/2480169/Bausch + Lomb announced the launch of Lumify (brimonidine tartrate ophthalmic solution 0.025%), the first and only over-the-counter (OTC) eye drop developed with low-dose brimonidine tartrate for the treatment of eye redness. “With the availability of Lumify, consumers now have an in
- Sylentis Announces New Data on the Treatment of Allergic Conjunctivitishttps://modernod.com/news/sylentis-announces-new-data-on-the-treatment-of-allergic-conjunctivitis/2480172/At the ARVO meeting, Sylentis presented preclinical results on its RNAi therapy, demonstrating how SYL116011 acts on seasonal ocular allergies SYL116011, which is being researched for ocular allergies caused by pollen, reduces the symptoms related to allergy, such as swelling and tearing,
- Sylentis Presents New Results for the Treatment of AMDhttps://modernod.com/news/sylentis-presents-new-results-for-the-treatment-of-amd/2480173/Sylentis presented preclinical results of a new topically administered molecule (SYL1801), indicated for the treatment of age-related macular degeneration (AMD), at the ARVO meeting. Sylentis presented the abstract “Topical administration of siRNA targeting NRARP as a new treatment